The treatment leads to a reduction in ovarian cancer incidence, tumor sizes, and the number of tumors. It inhibits NF‐κB and STAT3 signaling pathways, induces the nuclear factor erythroid 2/heme oxygenase 1 antioxidant pathway, and results in fewer KRAS and HRAS mutations in ovarian tumors. This evidence concerns the gene KRAS and ovarian cancer.